Best Healthcare Stocks to Buy Right Now for Long-Term Growth

Source The Motley Fool

Key Points

  • They are among the top players in their respective corners of the healthcare sector.

  • Both should benefit in the long run as demand for medical products and services increases.

  • 10 stocks we like better than HCA Healthcare ›

Stocks that perform well over the long run tend to have several traits, such as a large, growing market where they have a strong presence, solid financial results, and a competitive moat. Investing in companies that fit that description and holding onto their shares, through thick and thin, can often lead to outstanding returns. With that as a backdrop, let's consider two healthcare stocks that seem to have what it takes to generate excellent long-term returns: HCA Healthcare (NYSE: HCA) and Abbott Laboratories (NYSE: ABT).

Physicians performing a surgery.

Image source: Getty Images.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

1. HCA Healthcare

Even as longevity science is an increasingly active field, it seems likely that humans will continue to get sick and need medical care for the foreseeable future. In fact, the demand for it should expand in the next few decades as the world's population ages. That's where HCA Healthcare comes in. The company runs a diversified network of healthcare facilities across the U.S. It is a leading player in this niche and benefits from a strong competitive edge thanks to its being deeply entrenched in the communities it serves, and having established relationships with third-party payers -- including government ones -- in an industry with significant regulatory barriers to entry.

HCA Healthcare generally records consistent revenue and earnings, and over the past year, the stock has soared on the back of excellent financial results. The company also continues to implement a strategy that has allowed it to grow its market share over the long run, which includes investing in cutting-edge technology.

Although HCA Healthcare's business is susceptible to legal and regulatory changes in the healthcare sector, including the risk that government programs will decrease reimbursement rates, potentially leading to lower revenue and margins, the company's business has handled that threat well in the past and is well-positioned to continue doing so, given its significant exposure to private third-party payers. So, the stock could perform well and offer excellent returns to patient investors.

2. Abbott Laboratories

Abbott Laboratories has an impressive track record of innovation. The medical device specialist markets products physicians use to diagnose and treat their patients -- and sometimes, products marketed directly to patients -- across several therapeutic areas, such as cardiovascular health and diabetes care. Some of Abbott's devices are among the leaders in their niches. These include the company's FreeStyle Libre, a franchise of continuous glucose monitoring (CGM) systems. The FreeStyle Libre has excellent prospects, given CGM's low penetration globally.

Abbott's future doesn't depend on a single franchise, though. The company will likely continue developing and marketing newer, better products, as it has in the past, leading to improved financial results over the long run. Abbott Laboratories also benefits from an economic moat stemming from patents on its devices, which grant it some degree of pricing power, as well as its deeply entrenched footprint (and reputation) in the healthcare industry. Lastly, Abbott Laboratories is a phenomenal income stock. The company is a Dividend King, or a corporation with 50 (or more) consecutive annual payout increases. Abbott is another top healthcare stock to hold onto for the long haul.

Should you buy stock in HCA Healthcare right now?

Before you buy stock in HCA Healthcare, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and HCA Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $518,530!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,069,165!*

Now, it’s worth noting Stock Advisor’s total average return is 915% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of April 1, 2026.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Trump Withdrawal Intent Reshapes Liquidity, Bitcoin Breaks $68,000 MarkUS and Iran signal ceasefire talks; Bitcoin breaks $68,000, expected to continue rebounding in the short term.On April 1, Bitcoin ( BTC) prices continued to rebound, strengthening further
Author  TradingKey
7 hours ago
US and Iran signal ceasefire talks; Bitcoin breaks $68,000, expected to continue rebounding in the short term.On April 1, Bitcoin ( BTC) prices continued to rebound, strengthening further
placeholder
Today’s Market Recap: US and Iran Signal Willingness to End Conflict, Three Major US Stock Indexes Surge, Dollar Ends Five-Day Winning StreakAs the U.S. and Iran signaled a de-escalation of their conflict, market risk appetite recovered significantly, with the three major U.S. stock indices rebounding sharply to record their l
Author  TradingKey
16 hours ago
As the U.S. and Iran signaled a de-escalation of their conflict, market risk appetite recovered significantly, with the three major U.S. stock indices rebounding sharply to record their l
placeholder
Brent: Forecast lifted with $150 risk – Societe GeneraleSociete Generale’s commodities team has revised its Oil outlook, warning Brent could spike towards $150/bbl in a higher‑for‑longer scenario if the Strait of Hormuz is shut for two months.
Author  FXStreet
Mar 31, Tue
Societe Generale’s commodities team has revised its Oil outlook, warning Brent could spike towards $150/bbl in a higher‑for‑longer scenario if the Strait of Hormuz is shut for two months.
placeholder
Australian Dollar advances as RBA Minutes flag more tighteningAUD/USD halts its five-day losing streak, trading around 0.6860 during the Asian hours on Tuesday. The pair advances as the Australian Dollar (AUD) receives support after the Reserve Bank of Australia released its March Meeting Minutes.
Author  FXStreet
Mar 31, Tue
AUD/USD halts its five-day losing streak, trading around 0.6860 during the Asian hours on Tuesday. The pair advances as the Australian Dollar (AUD) receives support after the Reserve Bank of Australia released its March Meeting Minutes.
placeholder
USD/JPY Hits 160.00 Mark, Will Japanese Government Intervene? Will the Currency’s Rally Be Contained?As of March 30, the US Dollar against the Japanese Yen ( USDJPY) continues to fluctuate at high levels near the 160 mark, with the Yen having fallen to a nearly one-year low. Expectations
Author  TradingKey
Mar 30, Mon
As of March 30, the US Dollar against the Japanese Yen ( USDJPY) continues to fluctuate at high levels near the 160 mark, with the Yen having fallen to a nearly one-year low. Expectations
goTop
quote